Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
CERo Therapeutics Holdings, Inc. - Common Stock
(NQ:
CERO
)
0.7299
+0.0299 (+4.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CERo Therapeutics Holdings, Inc. - Common Stock
< Previous
1
2
3
4
Next >
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
May 08, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
April 30, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
April 25, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
Top stock movements in today's session.
April 25, 2025
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
April 25, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Thursday's session: top gainers and losers
April 24, 2025
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Keep an eye on the top gainers and losers in Thursday's session.
April 24, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results
April 24, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 24, 2025
Via
Benzinga
Which stocks are gapping on Thursday?
April 24, 2025
The session on Thursday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook
April 24, 2025
Via
Benzinga
Topics
Stocks
Exposures
US Equities
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
April 24, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 24, 2025
Via
Benzinga
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
April 22, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
April 10, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
April 09, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
March 31, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Top movers in Thursday's pre-market session
March 27, 2025
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via
Chartmill
CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
March 27, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish
March 19, 2025
The compound will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia, with the first patient expected to be dosed in the first half of 2025.
Via
Stocktwits
CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services
March 19, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
March 13, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
March 13, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
March 13, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays
March 06, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14
March 05, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Highlights Progress
February 06, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
February 05, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Friday's after hours session: top gainers and losers
January 24, 2025
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
January 06, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.